FTRE
BEARISH
$9.38
Live
Fortrea Holdings Inc. · NASDAQ
Target $13.21
(+40.8%)
$3.97
52W Range
$18.67
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 10, 2026
Market cap
$877.03M
P/E
N/A
ROE
-102.4%
Profit margin
-36.2%
Debt/Equity
1.98
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
FTRE exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While valuation metrics like Price/Sales (0.32) and PEG (0.34) suggest the stock is deeply undervalued, this is offset by negative revenue growth (-5.20%), a negative ROE of -102.41%, and a current ratio below 1.0 (0.98), signaling liquidity risks. Despite a 'Buy' consensus from analysts with a target of $13.21, the combination of C-suite insider selling and a consistent failure to meet earnings estimates suggests a high-risk profile.
Key Strengths
Very low Price-to-Sales ratio (0.32) suggesting potential deep value
Low PEG ratio (0.34) if growth can be stabilized
Positive analyst sentiment with a target price of $13.21
Recent 1-year price recovery (+45.4%)
Positive operating margin (1.33%) despite net losses
Key Risks
Critical financial health (Piotroski F-Score 2/9)
Negative revenue growth both YoY and Q/Q
Liquidity risk with a current ratio of 0.98 and quick ratio of 0.87
Severe profitability collapse (ROE -102.41%, Profit Margin -36.21%)
High leverage with a Debt/Equity ratio of 1.98
AI Fair Value Estimate
Based on comprehensive analysis
$11.2
+19.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
25
Weak
65
25
20
15
0
AI Verdict
High Risk / Speculative Value
Key drivers: Poor Piotroski Score, Negative Revenue Growth, C-Suite Insider Selling, Liquidity Constraints
Confidence
90%
Value
65/100
Ref P/E, PEG, P/S
Positives
- P/S of 0.32 is extremely low
- Forward P/E of 9.91 is attractive if earnings materialize
Watchpoints
- Lack of current earnings makes P/E irrelevant
- Price/Book of 1.55 is moderate but not a bargain given the ROE
Future
25/100
Ref Growth rates
Positives
- Analyst target price suggests 40% upside
Watchpoints
- Revenue growth is negative (-5.20%)
- EPS growth is declining sharply (-50% YoY)
Past
20/100
Ref Historical trends
Positives
- 1-year recovery from 52-week lows
Watchpoints
- 5-year price collapse of -68.8%
- Poor earnings surprise track record (1/4 beats)
Health
15/100
Ref Piotroski F-Score, Current Ratio
Positives
- Operating margin remains slightly positive
Watchpoints
- Piotroski F-Score 2/9 is a major red flag
- Current ratio < 1.0 indicates potential short-term solvency issues
- Debt/Equity of 1.98 is high for the current profitability level
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- Zero dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$9.38
Analyst Target
$13.21
Upside/Downside
+40.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for FTRE and closest competitors.
Updated 2026-04-09
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
FTRE
Fortrea Holdings Inc.
Primary
|
-68.8% | -68.8% | +45.4% | -12.7% | +4.8% | -0.7% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
|
AMPH
Amphastar Pharmaceuticals, Inc.
Peer
|
-5.1% | -51.1% | -30.7% | -35.2% | -36.4% | -6.0% |
|
EVO
Evotec SE
Peer
|
-85.8% | -75.5% | -11.5% | -32.4% | -11.2% | +5.9% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
FTR
Fortrea Holdings Inc.
Primary
5Y
-68.8%
3Y
-68.8%
1Y
+45.4%
6M
-12.7%
1M
+4.8%
1W
-0.7%
ABU
Arbutus Biopharma Corporation
Peer
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%
AMP
Amphastar Pharmaceuticals, Inc.
Peer
5Y
-5.1%
3Y
-51.1%
1Y
-30.7%
6M
-35.2%
1M
-36.4%
1W
-6.0%
EVO
Evotec SE
Peer
5Y
-85.8%
3Y
-75.5%
1Y
-11.5%
6M
-32.4%
1M
-11.2%
1W
+5.9%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
9.91
PEG Ratio
0.34
P/B Ratio
1.55
P/S Ratio
0.32
EV/Revenue
0.67
EV/EBITDA
43.85
Market Cap
$877.03M
Profitability
Profit margins and return metrics
Profit Margin
-36.21%
Operating Margin
1.33%
Gross Margin
18.5%
ROE
-102.41%
ROA
-0.61%
Growth
Revenue and earnings growth rates
Revenue Growth
-5.2%
Earnings Growth
N/A
Q/Q Revenue Growth
-5.24%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.98
High debt
Current Ratio
0.98
Weak
Quick Ratio
0.87
Poor
Cash/Share
$1.87
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.7B
Gross Margin
19.8%
Op. Margin
1.3%
Net Margin
-4.9%
Total Assets
$2.7B
Liabilities
$2.2B
Equity
$0.6B
Debt/Equity
3.82x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
94%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-26
$0.09
-43.8% surprise
2025-11-05
$0.12
-25.7% surprise
2025-08-06
$0.19
+152.5% surprise
Healthcare Sector Comparison
Comparing FTRE against 205 companies in the Healthcare sector
(17 bullish, 70 neutral, 118 bearish)
Return on Equity (ROE)
-102.41%
This Stock
vs
-42.45%
Sector Avg
+141.3%
(Excellent)
Profit Margin
-36.21%
This Stock
vs
-18.49%
Sector Avg
+95.8%
(Superior)
Debt to Equity
1.98
This Stock
vs
4.76
Sector Avg
-58.3%
(Less Debt)
Revenue Growth
-5.2%
This Stock
vs
106.86%
Sector Avg
-104.9%
(Slower)
Current Ratio
0.98
This Stock
vs
3.53
Sector Avg
-72.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
FTRE
Fortrea Holdings Inc.
|
BEARISH | $877.03M | - | -102.4% | -36.2% | $9.38 | |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | Compare |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
BEARISH | $835.41M | 8.96 | 12.9% | 13.6% | $18.18 | Compare |
|
EVO
Evotec SE
|
BEARISH | $963.68M | - | -18.0% | -21.0% | $2.69 | Compare |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | Compare |
FTRE
Fortrea Holdings Inc.
BEARISH
Mkt Cap
$877M
P/E
-
ROE
-102.4%
Price
$9.38
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | RUSSELL ERIN L | Director | Stock Award | 23,946 | - |
| 2026-03-16 | MORAIS MARK A | Chief Operating Officer | Sale | 1,804 | $16,633 |
| 2026-03-16 | MCCONNELL JILL G | Chief Financial Officer | Sale | 1,804 | $16,633 |
| 2026-03-13 | MORAIS MARK A | Chief Operating Officer | Stock Award | 4,284 | - |
| 2026-03-13 | MCCONNELL JILL G | Chief Financial Officer | Stock Award | 4,284 | - |
| 2026-03-10 | PARKS ROBERT | Officer | Sale | 1,927 | $17,478 |
| 2026-03-10 | MCCONNELL JILL G | Chief Financial Officer | Sale | 5,061 | $45,903 |
| 2026-03-09 | PARKS ROBERT | Officer | Stock Award | 5,270 | - |
| 2026-03-09 | MCCONNELL JILL G | Chief Financial Officer | Stock Award | 15,283 | - |
| 2026-02-10 | MORAIS MARK A | Chief Operating Officer | Sale | 1,179 | $16,365 |
| 2026-02-10 | MCCONNELL JILL G | Chief Financial Officer | Sale | 881 | $12,229 |
| 2026-02-09 | MORAIS MARK A | Chief Operating Officer | Stock Award | 2,255 | - |
| 2026-02-09 | MCCONNELL JILL G | Chief Financial Officer | Stock Award | 1,685 | - |
RUSSELL ERIN L
Director
2026-03-20
23,946 shares
MORAIS MARK A
Chief Operating Officer
2026-03-16
1,804 shares
·
$16,633
MCCONNELL JILL G
Chief Financial Officer
2026-03-16
1,804 shares
·
$16,633
MORAIS MARK A
Chief Operating Officer
2026-03-13
4,284 shares
MCCONNELL JILL G
Chief Financial Officer
2026-03-13
4,284 shares
PARKS ROBERT
Officer
2026-03-10
1,927 shares
·
$17,478
MCCONNELL JILL G
Chief Financial Officer
2026-03-10
5,061 shares
·
$45,903
PARKS ROBERT
Officer
2026-03-09
5,270 shares
MCCONNELL JILL G
Chief Financial Officer
2026-03-09
15,283 shares
MORAIS MARK A
Chief Operating Officer
2026-02-10
1,179 shares
·
$16,365
MCCONNELL JILL G
Chief Financial Officer
2026-02-10
881 shares
·
$12,229
MORAIS MARK A
Chief Operating Officer
2026-02-09
2,255 shares
MCCONNELL JILL G
Chief Financial Officer
2026-02-09
1,685 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
11 analysts
Evercore ISI Group
2026-04-08
Outperform
Outperform
TD Cowen
2026-03-09
Hold
Buy
Barclays
2026-02-27
Equal-Weight
Equal-Weight
Baird
2026-02-27
Outperform
Outperform
TD Cowen
2026-01-22
Hold
Hold
Truist Securities
2026-01-08
Hold
Buy
Evercore ISI Group
2026-01-06
In-Line
Outperform
Mizuho
2025-12-18
Neutral
Neutral
Barclays
2025-12-15
Underweight
Equal-Weight
Citigroup
2025-12-11
Neutral
Buy
Past News Coverage
Recent headlines mentioning FTRE from our newsroom.
Newest → oldest
No matching news yet.